Reliability of Ki67-Labeling Index in Core Needle Biopsy Specimens of ER+/HER2- Breast Cancers.

IF 2.5 4区医学 Q2 PATHOLOGY Pathology International Pub Date : 2025-03-10 DOI:10.1111/pin.70005

Yumi Fukaya, Makoto Wakahara, Keiko Hosoya, Naoko Nouchi, Yoshihisa Umekita

{"title":"Reliability of Ki67-Labeling Index in Core Needle Biopsy Specimens of ER+/HER2- Breast Cancers.","authors":"Yumi Fukaya, Makoto Wakahara, Keiko Hosoya, Naoko Nouchi, Yoshihisa Umekita","doi":"10.1111/pin.70005","DOIUrl":null,"url":null,"abstract":"<p><p>The reliability of Ki67-labeling index (LI) in core needle biopsy (CNB) of ER+/HER2- invasive breast carcinoma (IBC) and factors affecting the discordance of Ki67-LI between CNB and surgical resection (SR) remain unsolved. We aimed to elucidate factors influencing the discordance of Ki67-LI between CNB and SR to classify ER+/HER2- IBC into luminal A-like (LumA) and luminal B-like (LumB). The cohort included 326 ER+/HER2- IBCs available with Ki67-LI data at both CNB and SR specimens. Survival analysis was performed on 122 patients. Spearman's rank correlation coefficient of Ki67-LI between them was 0.683. The log-rank test showed that patients with ER+/HER2- IBC with ≥ 20% Ki67-LI at CNB (p < 0.001) and SR specimens (p < 0.001) had significantly shorter disease-free survival. In multivariate analysis, a negative PgR (p = 0.002) and > 2 cm pathological tumor size (p < 0.001) had the most significant effect on the discordance of Ki67-LI between CNB and SR at 20% and 30% cutoffs, respectively. Histological grade III had a significant effect on the concordance between them (p = 0.01) at 20% cutoff. Ki67-LI assessment in CNB may be useful for classifying ER+/HER2- IBC into LumA and LumB with caution of some prognostic factors and cutoffs.</p>","PeriodicalId":19806,"journal":{"name":"Pathology International","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pin.70005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The reliability of Ki67-labeling index (LI) in core needle biopsy (CNB) of ER+/HER2- invasive breast carcinoma (IBC) and factors affecting the discordance of Ki67-LI between CNB and surgical resection (SR) remain unsolved. We aimed to elucidate factors influencing the discordance of Ki67-LI between CNB and SR to classify ER+/HER2- IBC into luminal A-like (LumA) and luminal B-like (LumB). The cohort included 326 ER+/HER2- IBCs available with Ki67-LI data at both CNB and SR specimens. Survival analysis was performed on 122 patients. Spearman's rank correlation coefficient of Ki67-LI between them was 0.683. The log-rank test showed that patients with ER+/HER2- IBC with ≥ 20% Ki67-LI at CNB (p < 0.001) and SR specimens (p < 0.001) had significantly shorter disease-free survival. In multivariate analysis, a negative PgR (p = 0.002) and > 2 cm pathological tumor size (p < 0.001) had the most significant effect on the discordance of Ki67-LI between CNB and SR at 20% and 30% cutoffs, respectively. Histological grade III had a significant effect on the concordance between them (p = 0.01) at 20% cutoff. Ki67-LI assessment in CNB may be useful for classifying ER+/HER2- IBC into LumA and LumB with caution of some prognostic factors and cutoffs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Pathology International 医学-病理学

CiteScore

4.50

自引率

4.50%

发文量

102

审稿时长

12 months

期刊介绍： Pathology International is the official English journal of the Japanese Society of Pathology, publishing articles of excellence in human and experimental pathology. The Journal focuses on the morphological study of the disease process and/or mechanisms. For human pathology, morphological investigation receives priority but manuscripts describing the result of any ancillary methods (cellular, chemical, immunological and molecular biological) that complement the morphology are accepted. Manuscript on experimental pathology that approach pathologenesis or mechanisms of disease processes are expected to report on the data obtained from models using cellular, biochemical, molecular biological, animal, immunological or other methods in conjunction with morphology. Manuscripts that report data on laboratory medicine (clinical pathology) without significant morphological contribution are not accepted.